Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01396941 · ClinicalTrials.gov registry record · NA

Effects of Sleep Duration and Architecture on Insulin Sensitivity

A NA study of Insulin Resistance, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT01396941: Completed NA study of Insulin Resistance, sponsored by University of California, San Francisco.

NCT01396941 is a NA study of Insulin Resistance that has completed, run by University of California, San Francisco. The registered enrollment target is 10 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01396941, a NA study of Insulin Resistance, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This pilot clinical trial will test the hypotheses that sleep restriction (for 5 nights), in comparison to "normal sleep", will: 1. Decrease peripheral insulin sensitivity and glucose tolerance, as measured by the hyperinsulinemic-euglycemic clamp and oral glucose tolerance test. 2. Decrease hepatic insulin sensitivity, as assessed by stable isotope studies of endogenous glucose production, gluconeogenesis and glycogenolysis.

Primary Outcome

Peripheral insulin sensitivity will be measured using the hyperinsulinemic-euglycemic clamp. Hepatic insulin sensitivity will be measured using stable isotope tracer studies.

Conditions Studied

Interventions

  • BEHAVIORAL Sleep restriction

Study Locations (1)

California

  • UCSF San Francisco General Hospital - San Francisco

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2011-05
Est. Completion 2014-12
Phase NA

What the finished NCT01396941 record still lists

NCT01396941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Sleep restriction is the first listed.

NCT01396941 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01396941 about?

NCT01396941 is a clinical study titled "Effects of Sleep Duration and Architecture on Insulin Sensitivity". This pilot clinical trial will test the hypotheses that sleep restriction (for 5 nights), in comparison to "normal sleep", will: 1. Decrease peripheral insulin sensitivity and glucose tolerance, as measured by the hyperinsulinemic-euglycemic clamp and oral glucose tolerance test. 2. Decrease hepati...

What is the current status of trial NCT01396941?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2011-05. Estimated completion is 2014-12.

What conditions does trial NCT01396941 study?

This clinical trial studies the following conditions: Insulin Resistance.

What interventions are being tested in trial NCT01396941?

The interventions under investigation include: Sleep restriction (BEHAVIORAL).

Who is sponsoring clinical trial NCT01396941?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01396941 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01396941's enrollment target sits among peer trials

10 112th of 120 higher than 8 of 120 other Insulin Resistance trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01396941, the US trial registry maintained by the National Library of Medicine. NCT01396941 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.